SMi Source Lesson Oncology: Melanoma

  • SMi Source lesson Oncology: Melanoma has the following microlearning topics

  • 1. Learning Objectives

    2. Introduction

    3. Anatomy and Pathophysiology

    4. Mechanisms of Disease Development and Progression: Genetic Mutations and Impact

    5. Mechanisms of Disease Development and Progression: Immune Evasion and Immunosuppression, Angiogenesis

    6. Mechanisms of Disease Development and Progression: Chemotherapy Resistance

    7. Melanoma Risk Factors: UV Exposure and Compromised Immune System

    8. Melanoma Risk Factors: Numerous Nevi and Genetics

    9. Patient Demographics

    10. Patient Demographics: Geography and Trends

    11. Clinical Evaluation: Visual Examination

    12. Clinical Examination: Cutaneous Melanoma

    13. Clinical Examination: Ocular Melanoma

    14. Superficial spreading melanoma

    15. Clinical Examination: Melanoma Detection and Location

    16. Clinical Examination: Lentigo Maligna Melanoma (LMM)

    17. Clinical Examination: Acral Lentiginous Melanoma (ALM)

    18. Clinical Examination: Biopsy

    19. Clinical Examination: Lymph Node Involvement

    20. Staging

    21. Prognostic Factors and Survival: Ulceration and Tumor Depth, Lymph Node Involvement

    22. Prognostic Factors and Survival: Factors and Statistics

    23. NCCN Guidelines - I IIa, IIb, and IIc

    24. NCCN Guidelines - Stage III and IV

    25. Treatment of Early-Stage Primary Melanoma

    26. Post-Surgical Adjuvant Therapy

    27. Metastatic Melanoma

    28. Response Rates of the Standard of Care Chemotherapies

    29. Metastatic Melanoma: Combination and Biologic Therapies

    30. Metastatic Melanoma: Biochemotherapy (BCT)

    31. Advanced Stage IV Melanoma: Second-Line Therapy

    32. Summary: Metastatic Melanoma Therapies

    33. Overview: Clinical Trials in Different Patient Populations

    34. Primary Melanoma IFN-α Adjuvant Therapy

    35. Adjuvant Therapy Trials: ECOG

    36. Adjuvant Therapy Trials: IFN-a

    37. Metastatic Melanoma

    38. Metastatic Melanoma: Single-Agent Chemotherapy

    39. Metastatic Melanoma:Darthmouth Regimen

    40. Metastatic Melanoma: CVD Regimen

    41. Metastatic Melanoma: PC Combination Regimen

    42. Metastatic Melanoma: Combination Regimens

    43. Combination Chemotherapy Trials in Metastatic Melanoma

    44. Combination Chemotherapy Trials in Metastatic Melanoma: Stage IV Melanoma

    45. Metastatic Melanoma: Biologics

    46. Metastatic Melanoma

    47. Metastatic Melanoma: IL-2

    48. Metastatic Melanoma: Biochemotherapy and Sequential vs. Concurrent BCT

    49. Metastatic Melanoma: Biochemotherapy (BCT)

    50. Metastatic Melanoma: BCT Pooled Analyses

    51. Combination Strategies

    52. Therapeutic Interventions Against Molecular Mechanisms of Melanoma Progression

    53. Summary of Current and Investigational Agents: Classic Chemotherapeutics and Immunotherapies

    54. Summary of Current and Investigational Agents: Targeted Agents, Vaccines, and Adoptive Cell Transfer

    55. Targeting the Molecular Pathways Controlling Tumor Cell Proliferation: c-Kit

    56. Targeting the Molecular Pathways Controlling Tumor Cell Proliferation: Importance of Combination Strategies

    57. Targeting the Molecular Pathways Controlling Tumor Cell Proliferation

    58. Investigational Clinical Trials

    59. Pro-Apoptotic Agents & Chemosensitization to Overcome Drug Resistance: Chemosensitization

    60. Pro-Apoptotic Agents & Chemosensitization to Overcome Drug Resistance: Pro-apoptotic Agents Under Investigation

    61. Investigational Clinical Trials: Targeting Angiogenesis

    62. Investigational Clinical Trials: Immunotherapy

    63. Investigational Clinical Trials: Toll-Like Receptor Agonists

    64. Investigational Clinical Trials: Adoptive Cell Therapy

    65. Investigational Clinical Trials: Therapeutic Cancer Vaccines

    66. Investigational Clinical Trials: Vaccines and New Targeted Therapies

    67. Melanoma: Conclusions